Shao D, Cheng Y, Yuan ZS, et al. - For patients with Stage ⅢB/IV EGFR-mutant non–small-cell lung cancer (NSCLC) receiving EGFR tyrosine kinase inhibitor (TKI) treatment, researchers determined the prognostic value of FDG-PET in this retrospective investigation. Among the 78 assessed patients with Stage ⅢB/IV EGFR-mutant NSCLC who got baseline and interim PET/CT examinations and treatment with EGFR-TKI therapy, the 1-year and 2-year progression-free survival (PFS) rates were 33.9% (28.6–39.2%) and 20.7% (16.1–25.3%), respectively. For prognosticating the PFS or non-durable clinical benefit (non-DCB) of patients undergoing EGFR-TKI treatment, multivariable analysis suggested the independent value of interim PET relevant factors ΔSUVmax and ΔSUVmean as risk factors. They identified the highest diagnostic value in ΔSUVmax for the prediction of non-DCB. The optimal cutoff values for ΔSUVmax and ΔSUVmean were 56.74% and 36.48%, respectively.